Grünenthal and Averitas Pharma announce initiation of Phase III study with QUTENZA to prepare label extension in the US for the treatment of post-surgical neuropathic pain finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } });
Aachen, Germany, 12 February
2021 / News Aktuell – Grünenthal has announced the successful extension of its existing €535 million term loan bank facilities. This amendment was conducted in the broader context of the company’s acquisition of the European rights (excluding Spain and the UK) to the lipid-lowering medication CRESTOR™ completed in February 2021. The term loan maturities are now aligned with Grünenthal’s Revolving Credit Facility maturity, which further extends its debt maturity profile. More than 60 percent of Grünenthal’s debt facilities now mature in 2024 or later.
“By extending the maturity of our financing, we have gained additional flexibility to further fund our growth strategy,” says Fabian Raschke, Chief Financial Officer of Grünenthal. „W
Grünenthal closes deal with AstraZeneca for European rights to CRESTOR (rosuvastatin)
AACHEN, Germany, Feb. 10, 2021 /PRNewswire/ Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR (excluding Spain and the UK) for a total consideration of up to US$ 350 million. Cardiovascular diseases are among the most burdensome diseases in Europe
1, said Gabriel Baertschi, CEO Grünenthal. With CRESTOR, we are proud to provide a meaningful therapy option to those patients. The completion of this acquisition is an important milestone for Grünenthal.
Under the terms of this agreement, Grünenthal has acquired the exclusive rights to market CRESTOR and its second brands in more than 30 European markets. Grünenthal will also take over bulk production and packaging for the defined markets by 2025. CRESTOR continues to generate significant revenues, total CRESTOR 2019 sales in the countries where rights were acquired were US$ 136 milli
Grünenthal closes deal with AstraZeneca for European rights to CRESTOR™ (rosuvastatin)
News provided by
Share this article
Share this article
AACHEN, Germany, Feb. 10, 2021 /PRNewswire/ Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR™ (excluding Spain and the UK) for a total consideration of up to US$ 350 million. Cardiovascular diseases are among the most burdensome diseases in Europe
1, said Gabriel Baertschi, CEO Grünenthal. With CRESTOR™, we are proud to provide a meaningful therapy option to those patients. The completion of this acquisition is an important milestone for Grünenthal.
Under the terms of this agreement, Grünenthal has acquired the exclusive rights to market CRESTOR™ and its second brands in more than 30 European markets. Grünenthal will also take over bulk production and packaging for the defined markets by 2025. CRESTOR™ continues to generate significant revenues, total CRESTOR
Florian Dieckmann new VP Global Communications at Grünenthal
AACHEN, Germany, Jan. 12, 2021 /PRNewswire/ Florian Dieckmann joined Grünenthal as the new Vice President and Head Global Communications on 1 January 2021. He succeeds Štepán Krácala, who transformed the research-driven pharmaceutical company s Communications department from 2018 until the end of last year. Florian Dieckmann now leads Grünenthal s communications activities across almost 30 markets worldwide, and manages the team at the company s headquarters in Aachen. He reports directly to CEO Gabriel Baertschi.
As a fully integrated pharmaceutical company, Grünenthal aims to further strengthen its research and innovation capacities in the field of pain therapy, and to tap into additional commercial growth opportunities in its core markets - particularly in Europe, the USA and Latin America. The company has completed several acquisitions and entered into a wide range of strategic partnerships in recent years. T